New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be presented, with nemolizumab demonstrating a ...

USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on the momentum, philanthropists recently gave a ...

MDCX READ THE FULL V.MDCX RESEARCH REPORT First Patient Randomized for Medicus Pharma’s Phase 2 Clinical Study (SKNJCT-003) ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to ...

Biotech startup Ahammune Biosciences has raised $5 Mn (about INR 41 Cr) in its Series A round led by pi Ventures.

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Masofaniten plus Enzalutamide Results in Increased rPFS On September ...

AI-assisted pathology will enable early, accurate diagnosis of liver disease and offer insights that predict which patients ...

Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which ...

Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compan ...

(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...

The trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as the trial advances, providing a ...